Literature DB >> 8655143

Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis.

T Tokino1, T Urano, T Furuhata, M Matsushima, T Miyatsu, S Sasaki, Y Nakamura.   

Abstract

We have isolated human cDNA and genomic clones of a gene termed p57KIP2, which is related to the p2I WAFI and p27 KIP1 genes that encode inducible inhibitors of cyclin-dependent kinase activity. The p57 gene contains three GC-rich introns of 166 bp, 566 bp, and 83 bp, and two of the four exons correspond to coding regions. Alternative splicing generates the heterogeneity in the translational initiations. As this gene has been localized to chromosomal band 11pI5.5, a region thought to be the location of a tumor suppressor gene(s) for carcinomas of the breast, bladder, and liver, we have examined a large number of tumors for genetic alterations of p57. Although no somatic mutation has been detected, we have found several normal variations in this gene, including four types of 12-bp in-frame deletions in the proline/alanine repeating domain, in which nearly 40 motifs, viz., 5'-CCGGCC-3', are tandemly repeated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8655143     DOI: 10.1007/bf02281873

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  37 in total

1.  2058 expressed sequence tags (ESTs) from a human fetal lung cDNA library.

Authors:  K Sudo; K Chinen; Y Nakamura
Journal:  Genomics       Date:  1994-11-15       Impact factor: 5.736

Review 2.  Triplet repeat mutations in human disease.

Authors:  C T Caskey; A Pizzuti; Y H Fu; R G Fenwick; D L Nelson
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

3.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

Review 4.  Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

5.  Correlation of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes.

Authors:  K Takita; T Sato; M Miyagi; M Watatani; F Akiyama; G Sakamoto; F Kasumi; R Abe; Y Nakamura
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

6.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

7.  Genomic structure of human mismatch repair gene, hMLH1, and its mutation analysis in patients with hereditary non-polyposis colorectal cancer (HNPCC)

Authors:  H J Han; M Maruyama; S Baba; J G Park; Y Nakamura
Journal:  Hum Mol Genet       Date:  1995-02       Impact factor: 6.150

8.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

Authors:  M H Lee; I Reynisdóttir; J Massagué
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

9.  p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.

Authors:  G J Hannon; D Beach
Journal:  Nature       Date:  1994-09-15       Impact factor: 49.962

10.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors.

Authors:  M V Ponce-Castañeda; M H Lee; E Latres; K Polyak; L Lacombe; K Montgomery; S Mathew; K Krauter; J Sheinfeld; J Massague
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

View more
  18 in total

1.  p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.

Authors:  W Hartmann; A Waha; A Koch; C G Goodyer; S Albrecht; D von Schweinitz; T Pietsch
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells.

Authors:  Capucine Van Rechem; Gaylor Boulay; Sébastien Pinte; Nicolas Stankovic-Valentin; Cateline Guérardel; Dominique Leprince
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

Review 3.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

4.  Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome.

Authors:  M P Lee; M DeBaun; G Randhawa; B A Reichard; S J Elledge; A P Feinberg
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

5.  Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors.

Authors:  D O'Keefe; D Dao; L Zhao; R Sanderson; D Warburton; L Weiss; K Anyane-Yeboa; B Tycko
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

Review 6.  Genomic imprinting and cancer.

Authors:  J A Joyce; P N Schofield
Journal:  Mol Pathol       Date:  1998-08

7.  Binding sites for adeno-associated virus Rep proteins within the human genome.

Authors:  R S Wonderling; R A Owens
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  Induction of cellular genes is mediated by the Bel1 transactivator in foamy virus-infected human cells.

Authors:  A Wagner; A Doerks; M Aboud; A Alonso; T Tokino; R M Flügel; M Löchelt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

9.  Alternative mechanisms associated with silencing of CDKN1C in Beckwith-Wiedemann syndrome.

Authors:  N Diaz-Meyer; Y Yang; S N Sait; E R Maher; M J Higgins
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

10.  Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation.

Authors:  Joseph M Scandura; Piernicola Boccuni; Joan Massagué; Stephen D Nimer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.